MannKind’s Inhaled Insulin Tied to Lung Function Concerns

MannKind Corp.’s inhaled diabetes drug, found to be effective against Type 2 diabetes, is linked to potential breathing problems that may limit its use in patients with lung diseases, U.S. regulators said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.